ESLA - NASDAQ

Estrella Immunopharma, Inc.

ESLA·NASDAQ

$1.17

+0.41%

HealthcareBiotechnology

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$50.34M

EPS-0.3500

P/E Ratio-3.34

Earnings Date06/03/2026

3.18M

Assets

3Y-68.0%

5Y-35.0%

10Y-35.0%

13.54M

Total Liabilities

352%

3Y+364.0%

5Y+127.0%

10Y+127.0%

-10.37M

Total Equity

-7312%

3Y-247.0%

5Y+897.0%

10Y+897.0%

Estrella Immunopharma, Inc. Funding & Solvency Profile

ESLA · NASDAQ

Current Assets

Cash & Cash Equivalents1.38M

Net Receivables0.00

Inventory0.00

Other Current Assets292.67K

Total Current Assets2 M

Non-Current Assets

Property, Plant & Equipment0.00

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets1.50M

Total Non-Current Assets2 M

Total Assets

3.18M

Financial Health Analysis

Current Ratio

0.12x

Warning: Liquidity concerns. Current assets may not be sufficient to cover short-term obligations.

Working Capital

-11866058

Negative working capital indicates short-term liabilities exceed short-term assets—potential liquidity stress.

Asset Composition

53% Current

Balanced asset mix between current and non-current assets, typical of many stable businesses.

Estrella Immunopharma, Inc. Balance Sheet

ESLA • NASDAQ

Estrella Immunopharma, Inc. Balance Sheet	Dec 2025	Dec 2024	Jun 2024	Dec 2022	Jun 2022
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	1.4M	916.9K	4.2M	40.8K	4.1M
Cash & Short-Term Investments	1.4M	916.9K	4.2M	40.8K	4.1M
Net Receivables	0.0	0.0	288.8K	0.0	0.0
Other Receivables	0.0	0.0	288.8K	0.0	0.0
Prepaids	0.0	0.0	0.0	11.6K	833.3K
Other Current Assets	292.7K	723.9K	0.0	0.0	0.0
Total Current Assets	1.7M	1.6M	4.5M	52.4K	4.9M
NON-CURRENT ASSETS
Long-Term Investments	0.0	0.0	0.0	9.7M	45.2M
Tax Assets	0.0	0.0	0.0	262.7K	0.0
Other Non-Current Assets	1.5M	1.5M	0.0	0.0	0.0
Total Non-Current Assets	1.5M	1.5M	0.0	9.9M	45.2M
Other Assets	0.0	0.0	0.0	0.0	-45.2M
Total Assets	3.2M	3.1M	4.5M	10M	4.9M
LIABILITIES
CURRENT LIABILITIES
Total Payables	554.8K	50.0	40.7K	51.2K	946.7K
Accounts Payable	554.8K	0.0	0.0	46.9K	945.6K
Other Payables	0.0	50.0	40.7K	4.3K	1.1K
Accrued Expenses	57.5K	14.1K	10.2K	420.8K	0.0
Short Term Debt	0.0	0.0	0.0	498.6K	0.0
Tax Payables	0.0	0.0	44.9K	51.2K	1.1K
Other Current Liabilities	12.9M	3M	129.7K	8.8M	0.0
Total Current Liabilities	13.5M	3M	180.7K	1.1M	946.7K
NON-CURRENT LIABILITIES
Deferred Tax Liabilities (Non-Current)	0.0	0.0	0.0	292.2K	0.0
Other Non-Current Liabilities	0.0	0.0	0.0	1.6M	5M
Total Non-Current Liabilities	0.0	0.0	0.0	1.8M	5M
Total Liabilities	13.5M	3M	180.7K	2.9M	6M
SHAREHOLDERS' EQUITY
Treasury Stock	-598.4K	-568.9K	-354.4K	0.0	0.0
Common Stock	3.8K	3.7K	3.7K	9.3M	18.0
Additional Paid-In Capital	27.2M	24.6M	24.1M	445.9K	34.3K
Retained Earnings	-37M	-23.9M	-19.5M	-2.3M	-1.1M
Other Total Stockholders' Equity	0.0	0.0	0.0	18.8M	0.0
Total Stockholders' Equity	-10.4M	143.7K	4.3M	7.1M	-1M
Total Equity	-10.4M	143.7K	4.3M	7.1M	-1M
SUMMARY
Total Liabilities & Equity	3.2M	3.1M	4.5M	10M	4.9M
Total Investments	0.0	0.0	0.0	9.7M	45.2M
Total Debt	0.0	0.0	0.0	498.6K	0.0
Net Debt	-1.4M	-916.9K	-4.2M	457.8K	-4.1M
Shares Outstanding	37,065,589	37,065,589	37,065,589	37,065,589	37,065,589

SEC Filings

ESLA - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-K/A 10-K/A 2025 FY (Amended) FY	April 30, 2026	December 31, 2025	2025	View Filing
10-K 10-K 2025 FY FY	March 18, 2026	December 31, 2025	2025	View Filing
S-1/A S-1/A (Amended) N/A	January 22, 2026	January 22, 2026		View Filing
S-1/A S-1/A (Amended) N/A	January 16, 2026	January 16, 2026		View Filing
8-K 8-K 2026 N/A	January 13, 2026	January 07, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 06, 2026	January 05, 2026	2026	View Filing
S-1 S-1 N/A	December 22, 2025	December 22, 2025		View Filing
8-K 8-K 2025 N/A	December 04, 2025	December 04, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	November 12, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 06, 2025	November 03, 2025	2025	View Filing

Showing 1 to 10 of 106 filings

Related Guides

Blog Categories

Continue your ESLA research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.